Passa al contenuto
Merck

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

SML2263

Ladostigil tartrate

≥98% (HPLC)

Sinonimo/i:

(3R)-(N-Propargylaminoindan-5-yl)-ethyl methyl carbamate tartrate (2:1), TV-3326, TV3326

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
5 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
72,70 €
61,79 €
25 mg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
292,00 €
248,20 €

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C16H20N2O2 · 0.5C4H6O6
Numero CAS:
209394-46-7
Peso molecolare:
347.39
UNSPSC Code:
12352200
MDL number:
MFCD22741393
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

61,79 €

Prezzo di listino72,70 €Risparmia il 15%
Promozione valida solo online
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
​
Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N([C@@H]3CCc4c3cc(cc4)OC(=O)N(CC)C)CC#C.N([C@@H]1CCc2c1cc(cc2)OC(=O)N(CC)C)CC#C.O[C@H]([C@@H](O)C(=O)O)C(=O)O

InChI

1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

InChI key

PRLVBVAJMQZMJN-OGOSNNLPSA-N

Biochem/physiol Actions

Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor.[1] It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages.[1] It provides protection to cardiomyocytes.[2] Ladostigil has neuroprotective functionality and has the potential to treat mild cognitive impairment (MCI) and spatial memory deficits development.[3] It also exhibits protective effects during oxidative and nitrative stress.[3]
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
SML2351SML0881M5449
Ladostigil tartrate ≥98% (HPLC)

Sigma-Aldrich

SML2263

Ladostigil tartrate

Dabigatran etexilate ≥98% (HPLC)

Sigma-Aldrich

SML2351

Dabigatran etexilate

Rivastigmine tartrate ≥98% (HPLC)

Sigma-Aldrich

SML0881

Rivastigmine tartrate

MKT-077 ≥98% (HPLC), powder

Sigma-Aldrich

M5449

MKT-077

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: 15 mg/mL, clear

solubility

H2O: 10 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

orange to red

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000185160
0000185162
0000167599
0000185162
0000185160

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Rony Panarsky et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 488-498 (2012-03-29)
Impaired mitochondrial function accompanied by microglial activation and the release of nitric oxide (NO) and pro-inflammatory cytokines has been reported in Alzheimer's disease, its prodromal phase of Mild Cognitive Impairment (MCI) and in aged rats. The present study showed that
Orly Weinreb et al.
British journal of pharmacology, 173(13), 2080-2094 (2015-09-04)
Alzheimer's disease (AD) is accepted nowadays as a complex neurodegenerative disorder with multifaceted cerebral pathologies, including extracellular deposition of amyloid β peptide-containing plaques, intracellular neurofibrillary tangles, progressive loss of cholinergic neurons, metal dyshomeostasis, mitochondrial dysfunction, neuroinflammation, glutamate excitoxicity, oxidative stress
Moussa B H Youdim
Experimental neurobiology, 22(1), 1-10 (2013-04-16)
Present anti-PD and -AD drugs have limited symptomatic activity and devoid of neuroprotective and neurorestorative property that is needed for disease modifying action. The complex pathology of PD and AD led us to develop several multi-target neuroprotective and neurorestorative drugs
Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKUGTIN
SML2263-25MG04061835504954
SML2263-5MG04061835504961

Domande

Recensioni

Nessuna valutazione

Filtri attivi